OmniAb ( NASDAQ:OABI – Get Free Report ) issued its earnings results on Friday. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, FiscalAI reports. The firm had revenue of $3.99 million for the quarter, compared to the consensus estimate of $3.49 million. OmniAb had a negative return on equity of 16.59% and a negative net margin of 115.12%.
Here are the key takeaways from OmniAb’s conference call:
2026 guidance was raised: OmniAb increased revenue guidance to $35 million–$39 million, reduced operating-expense guidance to $83 million–$87 million, and expects year-end cash of $53 million–$57 million, implying roughly break-even net cash flow for the year.
The company signed a new Eli Lilly ion-channel license that includes an upfront payment, up to $370 million in potential milestones , and tiered royalties; related service revenue is expected to begin in the fourth quarter.
Partner momentum continued, with 111 active partners and 433 active programs at quarter-end. OmniAb also reported 34 active clinical programs or approved products, more than $3 billion in contracted potential milestones, and the recent Chin...